

South Carolina
Department of Health and Human Services
Post Office Box 8206
Columbia, South Carolina 29202-8206

Pharmacy and Therapeutics (P&T) Committee Meeting
February 6, 2008
MINUTES

1. Call To Order

A meeting of the P&T Committee convened at 4:00 p.m. on Wednesday, February 6, 2008.

2. Welcome

Ed Behling, M.D. called the meeting to order and welcomed members, guests, and staff members.

Dr. Behling opened the meeting by stating that the P&T Committee meetings are held in compliance with the Freedom of Information Act's (FOIA) mandate that the public is notified when the public's business is being done, and that furthermore, the public has been notified that this facility is accessible to individuals with disabilities, and special accommodations could have been provided if requested in advance.

Mr. Assey introduced new P&T members, Jody Bolinger, M.D. and Charles Raine III, M.D.

Mrs. Forkner thanked the committee for their service. The Medicaid program had been on a decreasing trend, mostly due to the implementation of Medicare Part D, but is now on an increasing trend. Her goal is to keep the increase under 10% and the pharmacy expenditure represents a major portion of the Medicaid expenditure.

3. Committee Members Present:

Ed Behling, M.D.
Jody Bolinger, M.D.
Greg Browning, M.D.

Kelly Jones, Pharm.D.
Jim Lindsay, M.D.
Sara Lindsey, M.D.

Thomas Phillips, R.Ph.
Tan Platt, M.D.
Charles Raine III, M.D.
George E. Vess, Pharm. D.

DHHS Staff Present:

Emma Forkner, Director DHHS
Felicity Meyers, Deputy Director DHHS
O. Marion Burton, Medical Director
James M Assey, R.Ph.
Mike Blakely, R.Ph.
Deidra Singleton, J.D.
Byron Roberts, J.D.
Laurel Eddins
April Smith

Other Representation:

First Health Services - MaryRoberts, R.Ph.
Pharmaceutical Industry Speakers

4. Discussion Topics

A. Committee Meeting Minutes, Wednesday, November 7, 2007.

The draft minutes from the previous P&T Committee meeting were emailed to the members so that they could review the document prior to the meeting. The minutes were approved unanimously.

B. Public Comment

The rules for public comment were outlined. Dr. Behling instructed the speakers that presentations would be limited to three minutes. The Committee members' meeting packets included the speakers' curriculum vitae and signed disclosure declaration forms that were submitted prior to the meeting. The following speakers (in order of appearance) discussed the drugs listed below.

Company	Speaker	Drug
Novartis Pharmaceuticals	S. Troy Whitworth, Ph.D. Regional Scientific Director, Novartis Pharmaceuticals	Focalin XR®
Shire Pharmaceuticals	V. Shaw Evans, M.D. Medical Director, Lexington County Community Mental Health Center	Vyvanse®
McNeil Pediatrics	Donald Wouri, M.D. USC School of Medicine Developmental Pediatric Clinic	Concerta®
Eli Lilly & Co.	Donald Byrant Winters, M.D. Archdale Pediatrics Archdale, N.C.	Strattera®
Public Comment	Russell A. Barkley, Ph.D.	Strattera®

Dr. Frank R. Brown, III, Ph.D., M.D. spoke to the committee regarding the diagnosis and treatment of ADHD. Dr. Brown currently serves as the Director of the McLeod Institute for Neurodevelopment Pediatrics and spoke at the request of SC DHHS to provide additional information to committee members.

C. Drug Classes for Review

Mary Roberts, R.Ph., First Health Services Corporation, led the discussion for the following drug class: Attention Deficit Hyperactivity Disorder Therapy

The chart below represents the recommendations for the P & T Committee:

NO PA REQUIRED "PREFERRED"	PA REQUIRED
<i>Attention Deficit Hyperactivity Disorder Therapy</i>	
ADDERALL® XR AMPHETAMINE SALT COMBO CONCERTA® DEXMETHYLPHENIDATE HCL DEXTROAMPHETAMINE SULFATE FOCALIN® XR METADATE® ER METHYLIN® ER METHYLIN® TABLETS METHYLPHENIDATE ER METHYLPHENIDATE HCL STRATTERA® VYVANSE®	DAYTRANA® DESOXYN® DEXEDRINE® DEXTROSTAT® FOCALIN® METADATE® CD METHYLIN® SOLUTION METHYLIN® CHEWABLE PROVIGIL® RITALIN® RITALIN® LA RITALIN® SR

5. Old Business

Mr.Assey announced that classes for review at the upcoming meeting would be provided to the committee at the current meeting. This will start with the next meeting, and the committee will receive classes for review at the May meeting as soon as they are determined.

6. New Business

7. Resolved Items

Recommendations regarding PDL status for drugs in the following classes were approved for submission to DHHS. Attention Deficit Hyperactivity Disorder Therapy

8. Closing Comments

The next meeting will be held on Wednesday, May 7, 2008 at 4:00 p.m. at the same location.

9. Adjournment

The meeting adjourned at 5:50p.m.